NAF RELEASES LIST OF ELIGIBLE APPLICANTS FOR BMTC 46/2025 APTITUDE TEST. (PHOTO). #PRESS RELEASE.

Image
 PUBLIC ANNOUNCEMENT NAF RELEASES LIST OF ELIGIBLE APPLICANTS FOR BMTC 46/2025 APTITUDE TEST The Nigerian Air Force (NAF) wishes to inform the public that the list of eligible applicants for the Basic Military Training Course (BMTC) 46/2025 Aptitude Test has been published on the NAF Recruitment Portal. The list can be accessed via www.nafrecruitment.airforce.mil.ng . The Aptitude Test is scheduled for 13 December 2025 at 15 designated centres nationwide, commencing at 0700hrs. All shortlisted applicants are advised to arrive early and must come with their acknowledgement slips and required writing materials, as these are compulsory for participation. The NAF remains committed to a transparent, credible, and merit-based recruitment process aimed at selecting the most qualified young Nigerians to serve with honour and professionalism. Ehimen Ejodame Air Commodore  Director of Public Relations and Information, Headquarters, Nigerian Air Force. 9 December 2025

GSK SEEKS APPROVAL FOR WORLD'S FIRST MALARIA VACCINE.

A jogger runs past a signage for pharmaceutical giant GlaxoSmithKline (GSK) in London April 22, 2014. REUTERS/Luke MacGregor            According to sources,the company Glaxo Smith Kline {GSK} said today thursday that it is applying for regulatory approval for the world's first vaccine against malaria,designed for children in Africa.The British drugmaker said the shot called RTS,S,is intended exclusively for use outside the European union but will be evaluated by the European medicines Agency {EMA} in collaboration with World Health Organisation {WHO}.Malaria,a mosquito borne parastic disease,kills more than 600,000 people a year,mainly babies in the poorest parts of sub Saharan Africa.Experts have long hoped that scientists would be able to develop an effective vaccine against the disease,and scientists at GSK have been working on this one for 30 years.The WHO,has previously indicated it may recommend use of RTS,S from as early as 2015 if EMA drugs regulators back its license application.GSK has been developing RTS,S with the non profit PATH malaria vaccine initiative {MVI},with grant funding from the Bill and Melinda Gates foundation to MVI.The vaccine also contains an adjuvant,or booster,made by U.S biotech company Agenus,which received an undisclosed milestone payment for the regulatory submission.

Comments

Popular posts from this blog

SHAKIRA COVERS WOMEN'S HEALTH MAGAZINE,APRIL ISSUE.

INNOSON GIVES OUT BRAND NEW IVM G5 AND SALARY FOR LIFE TO THE MAN WHO PROPHESIED ABOUT HIS VEHICLE MANUFACTURING IN 1979.(PHOTO).

THE NEW OONI OF ILE-IFE,WILL NOT EAT THE HEART OF THE LATE OONI-PALACE CHIEFS.